The major goal of our laboratory is to understand the molecular mechanisms driving cancer progression and metastasis, and to translate these discoveries into clinically relevant therapeutic strategies. Our research focuses on patient-derived organoid (PDO) technologies, tumor microenvironment (TME) biology, and the identification of novel cancer drivers and therapeutic targets in solid tumors, with a particular emphasis on triple-negative breast cancer (TNBC). TNBC is an aggressive breast cancer subtype associated with poor prognosis and therapeutic resistance. Our laboratory investigates how genetic and epigenetic alterations reprogram cellular signaling networks to promote tumor plasticity, metastasis, and treatment resistance. To achieve these goals, we integrate PDO‑TME co-culture models, live-cell imaging, high-throughput proteomics, multiomic profiling, CRSIPR screening, and computational approaches. Our work has identified novel TNBC drivers and therapeutic targets, including TUBB2B, TCOF1 and ANLN, and continues to explore how epigenetic regulation and TME interactions shape cancer evolution and therapeutic response. Ultimately, our goal is to develop more effective and less toxic treatment strategies for cancer patients.